Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - κλοπιδογρέλη besilate - peripheral vascular diseases; stroke; myocardial infarction - Αντιθρομβωτικοί παράγοντες - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). Υψόμετρο τμήμα του st οξύ έμφραγμα του μυοκαρδίου, σε συνδυασμό με ΑΣΟ σε ιατρικά ασθενών επιλέξιμων για θρομβολυτική θεραπεία. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. Για περαιτέρω πληροφορίες ανατρέξτε στην παράγραφο 5.

Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

aripiprazole mylan pharma (previously aripiprazole pharmathen)

mylan pharmaceuticals limited - αριπιπραζόλη - schizophrenia; bipolar disorder - Ψυχοληπτικά - Το aripiprazole mylan pharma ενδείκνυται για τη θεραπεία της σχιζοφρένειας σε ενήλικες και σε εφήβους ηλικίας 15 ετών και άνω. Η αριπιπραζόλη mylan pharma ενδείκνυται για τη θεραπεία ήπιων έως σοβαρών μανιακών επεισοδίων σε Διπολική Διαταραχή τύπου ι και για την πρόληψη νέου μανιακού επεισοδίου σε ενήλικες που εμφάνισαν κυρίως μανιακά επεισόδια και των οποίων τα μανιακά επεισόδια ανταποκρίθηκαν στη θεραπεία με αριπιπραζόλη. Η αριπιπραζόλη mylan pharma ενδείκνυται για τη θεραπεία έως και 12 εβδομάδες με μέτρια έως σοβαρά μανιακά επεισόδια στη Διπολική Διαταραχή τύπου ι σε εφήβους ηλικίας 13 ετών και άνω.

Pirfenidone Viatris Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - Η πιρφενιδόνη - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - Ανοσοκατασταλτικά - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Dapagliflozin Viatris Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - Φάρμακα που χρησιμοποιούνται στον διαβήτη - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 και 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - υδροχλωρική κλοπιδογρέλη - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Αντιθρομβωτικοί παράγοντες - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

PIPERACILLIN + TAZOBACTAM/VIATRIS (4G/0.5G)/VIAL POWDER FOR SOLUTION FOR INJECTION/INFUSION Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

piperacillin + tazobactam/viatris (4g/0.5g)/vial powder for solution for injection/infusion

viatris limited (0000011780) damastown industrial park, mulhuddart, dublin 15 - piperacillin sodium; tazobactam sodium - powder for solution for injection/infusion - (4g/0.5g)/vial - piperacillin sodium (0059703843) 4g base; tazobactam sodium (8000001383) 500mg base - piperacillin and enzyme inhibitor

PIPERACILLIN + TAZOBACTAM/VIATRIS (2G/0.25G)/VIAL POWDER FOR SOLUTION FOR INJECTION/INFUSION Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

piperacillin + tazobactam/viatris (2g/0.25g)/vial powder for solution for injection/infusion

viatris limited (0000011780) damastown industrial park, mulhuddart, dublin 15 - piperacillin sodium; tazobactam sodium - powder for solution for injection/infusion - (2g/0.25g)/vial - piperacillin sodium (0059703843) 2g base; tazobactam sodium (8000001383) 250mg base - piperacillin and enzyme inhibitor

DONAROT PD.OR.SD 1,884(1,5)G/SACHET Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

donarot pd.or.sd 1,884(1,5)g/sachet

viatris healthcare limited, ireland damastown industrial park, - dublin - glucosamine sulfate - pd.or.sd (ΚΟΝΙΣ ΜΙΑΣ ΔΟΣΗΣ ΓΙΑ ΠΟΣΙΜΟ ΥΓΡΟ) - 1,884(1,5)g/sachet - glucosamine sulfate 1,884g - glucosamine

DONAROT F.C.TAB 750MG/TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

donarot f.c.tab 750mg/tab

viatris healthcare limited, ireland damastown industrial park, - dublin - glucosamine sulfate sodium salt - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 750mg/tab - glucosamine sulfate sodium salt 942mg - glucosamine

IMOVANE F.C.TAB 7,5MG/TAB Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

imovane f.c.tab 7,5mg/tab

viatris healthcare limited, ireland damastown industrial park, - dublin - zopiclone - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 7,5mg/tab - zopiclone 7,5mg - zopiclone